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Abstract: Antibiotic lock therapy (ALT) for the prevention and treatment of catheter-related
bloodstream infections is a simple strategy in theory, yet its real-world application may be delayed
or avoided due to technical questions and/or logistical challenges. This review focuses on these
latter aspects of ALT, including preparation information for a variety of antibiotic lock solutions
(ie, aminoglycosides, beta-lactams, fluoroquinolones, folate antagonists, glycopeptides, glycylcyclines, lipopeptides, oxazolidinones, polymyxins, and tetracyclines) and common clinical issues
surrounding ALT administration. Detailed data regarding concentrations, additives, stability/
compatibility, and dwell times are summarized. Logistical challenges such as lock preparation
procedures, use of additives (eg, heparin, citrate, or ethylenediaminetetraacetic acid), timing of
initiation and therapy duration, optimal dwell time and catheter accessibility, and risks of ALT
are also described. Development of local protocols is recommended in order to avoid these
potential barriers and encourage utilization of ALT where appropriate.
Keywords: antibiotic lock, biofilm, bacteremia, catheter-related bloodstream infection
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The prevention and management of catheter-related bloodstream infections (CRBSI)
is a significant health care challenge. CRBSI occur at an estimated rate of 41,000
infections in US hospitals annually.1 This rate varies based on factors such as hospital
bed size, medical school affiliation of the hospital, and type of unit/facility (eg, burn
critical care unit, inpatient medical ward, rehabilitation facility). In US medical and
surgical units of any acuity level, the most recent data from 2012 estimate the mean
incidence rate of CRBSI at 0.8 to 0.9 per 1,000 central line days.2 However, patients
in both medical and surgical critical care units are at higher overall risk of developing
CRBSI compared to similar patient populations in inpatient wards due to increased
central venous catheter (CVC) utilization, averaging 0.35–0.59 central line days per
1 patient-day compared to only 0.15–0.17 in inpatient wards.2 Among critically ill
patients, those in burn units or long-term care acute care hospitals are at particularly
high risk of developing CRBSI (mean rates of 3.4 and 1.6 CRBSI per 1,000 central
line days, respectively). While overall CRBSI rates appear to have decreased in the
last 10–15 years,3 they remain a substantial source of morbidity and mortality in the
health care system.
Clinical practice guidelines recommend antibiotic lock therapy (ALT) for both
prevention and treatment of catheter-related infections (CRI).4,5 Guidelines from
the Centers for Disease Control and Prevention recommend ALT as prophylaxis for
patients with long-term catheters and a history of multiple CRI despite maximal efforts
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to follow aseptic technique.4 Guidelines from the Infectious
Diseases Society of America (IDSA) for the diagnosis
and management of CRI recommend antibiotic locks as
adjunctive therapy specifically for catheter salvage in cases
where the catheter is not removed.5 CVC removal remains
first-line therapy for management of CRI, especially in
cases of Staphylococcus aureus and resistant gram-negative
pathogens, including Pseudomonas aeruginosa. Bustos et al
have previously reviewed the diagnosis and treatment of CRI
in detail.6 This review focuses on the technical aspects of
ALT for prevention and treatment of CRBSI in particular,
including solution preparation and logistical challenges
regarding administration. Details regarding non-antibiotic
lock solutions, including antiseptic agents (eg, ethanol) and
antifungals, are not discussed in this review.

Antibiotic activity against biofilms
Intravascular catheters and other implanted medical devices
routinely develop microbial biofilms on their inert surfaces.
A biofilm is defined as a microbial community with cells
attached to a substratum or each other and embedded in
a matrix of extracellular polymeric substances (EPS), or
glycocalyx. EPS density varies within the biofilm itself,
appearing densest in deeper layers immediately surrounding
the colonies of microorganisms. Its density decreases in more
superficial layers, leading to the formation of water channels
in and around the biofilm matrix.7 Such channels allow for
the transfer of nutrients, waste products, quorum-sensing
molecules, and other substances (including antibiotics),
similar to the function of a circulatory system in a multicellular organism.
Biofilms represent a form of adaptive resistance resulting
in a significant reduction of antibiotic susceptibility by tento 1,000-fold (based on minimal inhibitory concentrations
[MIC]). The exact mechanisms of antibiotic resistance within
biofilms remain unclear, yet a common hypothesis is subtherapeutic exposure of biofilm cells to antibiotics. Biofilms may
slow the distribution of antibiotics via charge interaction, size
exclusion, viscosity of the matrix, and possible adsorption to
proteins. EPS may also inactivate antibiotic molecules prior
to reaching biofilm cells. Table 1 summarizes the biofilm penetration of select antibiotics. The extent of penetration varies
widely (range 0%–100%), being excellent with agents such as
fluoroquinolones and rifamycins, variable with beta-lactams
and vancomycin, and attenuated with aminoglycosides.
This variability is likely due to the heterogeneity in biofilm
composition, the physiochemical properties of antibiotics,
and study design. Individual biofilms are a complex mixture
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of polysaccharides (eg, alginate), proteins, and DNA, with
significant inter- and intra-species composition variability.
Due to the high content of polyanionic substances, positively
charged drugs (eg, aminoglycosides) may bind to EPS and
exhibit a particularly attenuated distribution into biofilm.8
Differences in study methodology may also account for the
wide range of observed penetration, including aspects such as
the site (eg, edge or center of the biofilm) and timing (eg, 1,
6, 24, 72 hours, or continuously) of antibiotic concentration
measurement. Further studies have suggested that not only
the extent, but also the attenuated rate of antibiotic penetration may play a role in antibiotic resistance.9
Alterations in drug penetration are not the sole factor determining antibiotic resistance in biofilms. Biofilm
cells are often inherently more resistant to antibiotics than
planktonic cells. They may express additional resistance
factors (increased efflux pumps, stress response regulons,
inactivating enzymes) and exhibit a slower growth rate. Due
to the growth-dependent mechanisms of action of most antibiotics, the killing effect is often diminished in these sessile
biofilm cells. The multifactorial nature of biofilm resistance
to antibiotics is well-illustrated by data suggesting biofilm
penetration is unrelated to the ability of the antibiotic to
disrupt biofilm or kill biofilm cells.10,11 One study showed
ampicillin did not penetrate the biofilm of a wild-type strain
of Klebsiella pneumoniae (0% penetration), but was able to
rapidly penetrate the biofilm of a mutant K. pneumoniae strain
where beta-lactamase activity was eliminated (80%–100%
penetration).11 Even so, beta-lactamase–negative biofilm
cells with adequate ampicillin exposure displayed resistance
to ampicillin when compared to beta-lactamase–negative
planktonic cells, suggesting poor penetration alone did not
account for the observed resistance.11 Alternatively, streptomycin, an agent with poor biofilm penetration of 0%–60%, has
exhibited comparable biofilm removal and killing (14%–17%
and 15%–40%, respectively) as the readily penetrating
agent, ciprofloxacin (100% penetration, 12%–23% removal,
14%–36% killing).10 Thus, the ideal antibiotic for treatment of
biofilm should display adequate penetration into EPS as well
as a potent activity against biofilm cells. The antimicrobial
effect of potential additives, such as ion chelators like ethylenediaminetetraacetic acid (EDTA) and citrate, should also be
considered. Such agents have been shown to disrupt biofilm
and exhibit synergistic activity with antibiotics.12,13

Antibiotic lock solutions
In general, antibiotic lock solutions combine a highly concentrated antibiotic (100–1,000 times planktonic MIC) with
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Table 1 Summary of biofilm penetration for select antibiotics
Antibiotic class/agent
Fluoroquinolones
Ciprofloxacin

Levofloxacin
Rifamycins
Rifampin
Oxazolidinones
Linezolid
Lipopeptides
Daptomycin
Tetracyclines
Tetracycline
Macrolides
Erythromycin
Beta-lactams
Ampicillin

Oxacillin
Piperacillin
Cefotaxime
Imipenem
Glycopeptides
Vancomycin

Aminoglycosides
Streptomycin
Tobramycin
Gentamicin
Amikacin

Microorganism

Extent of penetration

Rate of penetration

Reference

Bacillus cereus, Pseudomonas fluorescens
Pseudomonas aeruginosa
P. aeruginosa
Klebsiella pneumoniae
Staphylococcus aureus, Staphylococcus epidermidis
P. aeruginosa

100%
100%
25%–50%
80%–100%
86%–100%
100%

NR
Rapid
Rapid
Rapid
NR
Rapid

10
74
75
11
76
75

S. epidermidis

79% to .90%

Rapid

77,78

S. epidermidis

∼100%a

Rapid

79

S. epidermidis

$100%b

Rapid

80

B. cereus, P. fluorescens

88%–93%

NR

10

B. cereus, P. fluorescens
S. epidermidis

72%–86%
45%–93%

NR
Variable/slow

10
81

K. pneumoniae
(beta-lactamase positive)
K. pneumoniae
(beta-lactamase negative)
S. aureus, S. epidermidis
P. aeruginosa
P. aeruginosa
S. aureus, S. epidermidis
P. aeruginosa

0%

NA

11

80%–100%

Rapid

11

,70%
50%–100%
0%–15%
68%–70%
50%–100%

NR
Rapid
NR
NR
Rapid

76
75
82
76
75

S. aureus, S. epidermidis
S. epidermidis
S. aureus

,70%
Adequatec
Adequateb,d

NR
Slow
Slow

76
77,83
9

B. cereus, P. fluorescens
P. aeruginosa
P. aeruginosa
P. aeruginosa
S. aureus, S. epidermidis

0%–60%
40%
,25%
,25%
79%–98%

NR
Slow
Slow
Slow
NR

10
74
75
75
76

Notes: aComparable penetration compared to isolates of planktonic cells; bmeasured as intensity of fluorescence using confocal microscopy or other methods; cvancomycin
concentrations reportedly exceeded the minimal inhibitory concentrations and minimal bactericidal concentrations for tested isolates; drepresents vancomycin concentrations
from 15–45 μg/mL.
Abbreviations: NA, not applicable; NR, not reported.

an anticoagulant to allow for local instillation into the catheter lumen. The solution is allowed to dwell or is “locked”
while the CVC is not in use to prevent colonization or sterilize a previously infected catheter. ALT is often utilized in
clinical practice in a prophylactic modality to prevent luminal colonization and subsequent CRBSI. This practice has
demonstrated significant benefit in hemodialysis-dependent
patients and those with indwelling CVC for intravenous
(IV) chemotherapy and total parenteral nutrition (TPN).5,14,15
ALT is also an option in the management of CRBSI as an
adjunct to systemic antibiotics, increasing rates of catheter

Infection and Drug Resistance 2014:7

salvage.5,16 Although there is wide variability in clinical utilization of ALT among infectious diseases specialists, nearly
40% report attempting catheter salvage with ALT.17

Ideal lock solution
The ideal lock solution should possess a number of
characteristics. Many, but perhaps not all, of these factors are
applicable for both treatment and prophylactic modalities.
1. Spectrum of activity should include common or targeted pathogens. Although the majority of CRBSI are
secondary to gram-positive organisms, protracted use of
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2.

3.

4.

5.

6.

7.

CVCs in high-risk patients increases the likelihood of
gram-negative and fungal pathogens.
Ability to penetrate or disrupt a biofilm. Especially
important in treatment, the ability to penetrate a biofilm
and demonstrate activity against biofilm cells at concentrations 100–1,000 times standard concentrations is
essential. Several lock solution additives, including ion
chelators such as citrate and EDTA, can also disrupt intact
biofilms.
Compatibility with anticoagulants. Not all CVC will
require the addition of an anticoagulant (eg, heparin)
to maintain patency; however, to decrease the risk of
occlusion, the ability to include a low-dose heparin
(eg, ,1,000 units/mL) or an alternative ion chelator
such as citrate will enhance the ability to broadly utilize
a lock solution.
Prolonged stability. The ability to prepare lock solutions
in bulk and apply extended expiration will enhance the
continuation of ALT at points of transitions of care.
This will be important for a pharmacy to maximize
cost-effective use of lock therapy. Storage at room
temperature as opposed to refrigeration is an additional
advantage.
Low risk of toxicity and adverse events. The small
volumes used in the intraluminal space do not lend
themselves to high risk of toxicity. However, higher
concentrations of specific agents (eg, aminoglycosides
and citrate) have been associated with significant toxicity and should be avoided when using ALT.18,19 There
is additional concern if these solutions are flushed as
opposed to aspirated, which could expose the patient to
higher concentrations of anticoagulants (eg, heparin).
Ethanol at higher concentrations may be associated with
minor adverse events, especially in low-weight neonates.14 Catheter occlusion is another possible adverse
event with ALT, especially in the absence of a low-dose
anticoagulant in solution.
Low potential for resistance. Although there is likely
minimal systemic exposure of the antibiotic lock solution if aspirated with each exchange, use of agents with
a low risk for development of resistance is important.
In a treatment modality, if the systemic antibiotic is
also used concurrently as a component of the lock
solution, concern for resistance is diminished.
Cost-effectiveness. Use of certain agents (eg, linezolid,
daptomycin) may be cost-prohibitive, especially when
used on a larger population in a prophylactic modality.
Careful consideration on maximizing compounding
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efficiency and stability should be done prior to initiating
lock therapy with such high-cost agents.

Antibiotics in solution: stability
and compatibility
Despite the variability in quality and quantity of data, many
antibiotics have been investigated in lock solutions in both
in vitro models and in clinical studies. Table 2 provides a
detailed, referenced summary of the available data on antibiotic lock solutions. In vitro or animal data were included
only when antibiotics were combined with an additive. In
vivo data were included if a unique concentration of the lock
solution was used. Comments on dwell time and duration of
use are included when available for in vivo studies. Of note,
many stability studies are conducted under varying conditions, including temperature (eg, 4°C vs 37°C), exposure
duration, and storage conditions (eg, glass vs polyurethane
catheter) and should be interpreted accordingly.
Beta-lactams have been studied extensively in lock solutions. Ampicillin and cefazolin have proven stability and
compatibility in combination with heparin at varying concentrations and may offer options for management of susceptible
gram-positive pathogens. Cefazolin and tissue plasminogen
activator (TPA) have been combined in a lock solution.20
Cefotaxime and ceftazidime have each been studied in combination with heparin, including several clinical studies with
ceftazidime-based lock therapy.21,22 Absorption into plastic
polymers has been described; yet despite this apparent loss of
antibiotic, ceftazidime concentrations expected to be active
against biofilm-producing organisms were achieved 21 days
postinstillation.22,23 Beta-lactams with extended spectrums
including piperacillin, piperacillin/tazobactam, and ticarcillin/
clavulanate have also been studied in combination with
heparin.23–27 Cefepime has only been investigated in a single
in vitro model without additives.28 There is a general lack
of data regarding carbapenems in lock solutions. A single
clinical study of imipenem/cilastatin in combination with
heparin and an unpublished abstract suggesting meropenem
and heparin stability and compatibility in a lock solution are
available.29,30 More data are needed with carbapenem-based
solutions as CRBSI secondary to multi-drug resistant organisms (MDRO) with limited treatment options are certain to
increase over time.
Aminoglycosides, specifically amikacin, gentamicin, and
tobramycin, have been studied extensively with a number
of additives, including heparin, citrate, TPA, and other antimicrobials. Aminoglycosides have proven effectiveness in
multiple in vitro models and are among the most commonly
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Powered by TCPDF (www.tcpdf.org)

Infection and Drug Resistance 2014:7
0.5 mg/mL

83.3 mg/mL,
166.6 mg/mL
100 mg/mL
2 mg/mL

Ticarcillin/clavulanate23

Nafcillin86

Cloxacillin87

Mezlocillin88

10 mg/mL
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No additives

Heparin 1,000 units/mL

No additives

Heparin 100 units/mL

Heparin 100 units/mL

Heparin 400 units/mL

100 mg/mL

Piperacillin/tazobactam27

Heparin 10 and
5,000 units/mL

10, 20, 40 mg/mL

Piperacillin24–26

Heparin 2,500 units/mL

5 mg/mL

No additives
Heparin 10 units/mL

5 mg/mL
2 mg/mL

Amoxicillin25

Heparin 10 and
5,000 units/mL

10 mg/mL

Ampicillin24,84,85

Heparin 2,500 and
5,000 units/mL

Additives and
concentrations

50,000 units/mL

Antibiotic
concentrations

Penicillins
Penicillin G25

Antibiotic class/agent

Table 2 Summary of available in vitro and in vivo data on antibiotic lock solutions

Visual confirmation of physical compatibility

Visual confirmation of physical compatibility

Bioassay stability sampling confirmed ,10%
loss of activity at 10 days at 25°C and 37°C in
polystyrene test tubes; addition of susceptible
bacteria had no impact on stability
Visual confirmation of physical compatibility

Visual confirmation of physical compatibility

Physically stable (visual confirmation) for 14 days
at 4°C and 37°C; yellow color reported at day
3 with piperacillin 40 mg/mL; heparin stable
for 14 days based on aPTT measures with
piperacillin 40 mg/mL
Visual confirmation of physical compatibility

Visual confirmation of physical compatibility

Visual confirmation of physical compatibility

Physically stable (visual confirmation) for 14 days
at 4°C and 37°C; yellow color reported at day 3;
heparin stable for 14 days based on aPTT measures

Visual confirmation of physical compatibility

Stability comments

Dwell time of 12 hours daily;
average duration 8 days
Dwell time up to 96 hours
between HD sessions
Dwell time 12–24 hours;
duration 10–14 days

Dwell time up to 72 hours
between HD sessions; duration
2–3 weeks with systemic
antibiotics
Two case reports; dwell time
of a minimum of 12 hours per
day; duration of 10 days with
systemic antibiotics

Dwell time up to 6 hours,
solution aspirated then replaced
to target continuous lock
Dwell time up to 72 hours
between HD sessions; duration
2–3 weeks with systemic
antibiotics

Dwell time up to 72 hours
between HD sessions; duration
2–3 weeks with systemic
antibiotics

Dwell time/duration
(if applicable)

(Continued)

Case series
(one report)

Case series
(6 reports)
In vivo study

In vitro bioassay
stability study

Case report

In vitro
bioactivity study

Single case
report

Case report
In vivo study

In vitro
bioactivity study

Case report

Type of
investigation(s)

Dovepress
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TPA 1 mg/mL
Heparin 5,000 units/mL

Gentamicin 1 mg/mL and
heparin 2,500 units/mL
Heparin 2,500 units/mL
Heparin 10 units/mL
Heparin 100 units/mL

5 mg/mL
5 mg/mL

5 mg/mL

5 mg/mL
5 mg/mL
0.5 mg/mL

Heparin 100 units/mL

Gentamicin 5 mg/mL and
heparin 1,000 and
5,000 units/mL

5 mg/mL

0.5 mg/mL

Heparin 5,000 units/mL

10 mg/mL

Ceftazidime21–23,86,95,97,98

Heparin 10 and
5,000 units/mL

10 mg/mL

Cephalosporins
Cefazolin20,21,23,24,45,84,89–96

Heparin 10–10,000 units/mL

Additives and
concentrations

20 mg/mL

Antibiotic
concentrations

Flucloxacillin38

Antibiotic class/agent

Table 2 (Continued)

Bioassay stability sampling confirmed ,10%
loss of activity at 3 days at 25°C and 37°C in
polystyrene test tubes; 30%–38% loss of
activity at 7 days at 37°C

Bioassay stability sampling confirmed #10% loss
at 10 days at 25°C and 37°C in polystyrene test
tubes; addition of susceptible bacteria had no
impact on stability

Visual confirmation of physical compatibility
up to 72 hours
Visual confirmation of physical compatibility

Visual confirmation of physical compatibility
up to 72 hours at 25°C and 37°C

,10% change in absorbance at 72 hours in
glass tubes; 27.3% change in absorbance at
72 hours in polyurethane catheter
Visual confirmation of physical compatibility;
combination with heparin 5,000 units/mL
confirmed to 72 hours at 37°C – a haze
reported when prepared at room temperature
within 30 minutes
Visual confirmation of physical compatibility
up to 48 hours
Visual confirmation of physical compatibility
up to 72 hours

Physically stable (visual confirmation) for 14 days
at 4°C; and 37°C; yellow color reported; heparin
stable for 14 days based on aPTT measures

Visual precipitation testing grid; authors comment
that “low-dose heparin” showed precipitation at
48 hours at 25°C and 37°C; combination with
heparin 4,000 units/mL stable for 72 hours

Stability comments

Dwell time of 8–12 hours/day;
duration 7–14 days

Dwell time up to 72 hours
between HD sessions
Dwell time up to 72 hours
between HD sessions

Dwell time up to 72 hours
between HD sessions

Dwell time up to 72 hours
between HD sessions; duration
up to 2 weeks

Dwell time/duration (if
applicable)

In vitro bioassay
stability study; in
vivo study

In vitro bioassay
stability study

In vivo study

In vitro and
animal models
of CRBSI; in vivo
study
In vivo study;
animal model of
CRSBI
In vivo study

In vivo study

In vivo study; in
vitro model of
CRSBI

In vitro stability
study

In vitro
bioactivity study

In vitro
bioactivity study

Type of
investigation(s)

Justo and Bookstaver
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Carbapenems
Imipenem/cilastatin29
Fluoroquinolones
Ciprofloxacin23,29,38,68,95,105,106

Cefotaxime99–104

Ceftriaxone86

Heparin 5,000 units/mL

No additives

10 mg/mL

83.3 mg/mL,
166.6 mg/mL,
and 333 mg/mL
83.3 mg/mL,
166.6 mg/mL
10 mg/mL

0.1–1 mg/mL

Heparin 10–10,000 units/mL

Heparin 5,000 units/mL
(reported as 5% heparin
sodium)
Heparin 100 units/mL

0.100 mg/mL

0.125 mg/mL

Heparin

50 mg/mL

Heparin 5,000 units/mL

No additives

Vancomycin 2.5 mg/mL and
heparin 2,500 units/mL
Heparin 2,500 units/mL

2.5 mg/mL
5 mg/mL

Heparin 100 units/mL

2 mg/mL

Visual stability at 7 days at 25°C and 37°C
in glass tubes confirmed for the following
combinations: ciprofloxacin 0.1 mg/mL + heparin
10–10,000 units/mL; ciprofloxacin 0.2 mg/mL +
heparin 1,000–10,000 units/mL; ciprofloxacin
0.4–0.6 mg/mL + heparin 5,000–10,000 units/mL

Bioassay stability sampling confirmed no loss
of activity at 10 days at 25°C and 37°C in
polystyrene test tubes; addition of susceptible
bacteria had no impact on stability; ciprofloxacin
concentrations .0.125 μg/mL formed visual
precipitation with heparin

Visual confirmation of physical compatibility

Visual confirmation of physical compatibility

Visual confirmation of physical compatibility; one
study stored lock solutions under refrigeration
prior to instillation in HD port. Chemical/
physical stability confirmed at 4°C; .10%
degradation at 24 hours at 27°C and 40°C

Visual confirmation of physical compatibility; authors
state up to 72 hours at 37°C (unpublished)
10.6%–12.9% change in absorbance at 48 and
72 hours at 37°C in glass tubes, respectively;
31.9%–40.2% change at 48 and 72 hours in
polyurethane catheters, respectively

Visual confirmation of physical compatibility

Concentrations from aspirated lock after
#15 days and #21 days in situ remained
234 μg/mL and 110 μg/mL, respectively

Dwell time up to 72 hours
between HD sessions; duration
of 15 days

Dwell time of 12 hours daily;
average duration of 8 days
Dwell time up to 72 hours
between HD sessions

Dwell time of 12 hours daily;
average duration of 8 days

Dwell time up to 72 hours
between HD sessions
Dwell time up to 72 hours
between HD sessions

Continuous dwell times of
2–34 days (median =17 days)

(Continued)

In vitro stability
study

In vitro bioassay
stability study

In vivo study

In vivo study

In vivo study;
in vitro stability
study

Case series

Case series

In vitro stability
study

In vivo study

In vivo study with
residual antibiotic
concentration
analysis
In vivo study
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Aminoglycosides
Amikacin18,19,38,40,65,66,68,70,88,107–109

Levofloxacin27,47

Antibiotic class/agent

Table 2 (Continued)

Heparin 100 units/mL

5 mg/mL

No additives

Clarithromycin 200 mg/mL ±
heparin 1,000 units/mL

0.05, 3.2 mg/mL

1.5 mg/mL

Heparin 5,000 units/mL

10 mg/mL

No additives

No additives

10 mg/mL

1 mg/mL

Heparin

2 mg/mL

Teicoplanin 0.02–10 mg/mL ±
heparin 7–10,000 units/mL

Visual confirmation of compatibility at 96 hours
at 37°C

Heparin 2,500 units/mL

1 mg/mL

0.02–4 mg/mL

Immediate precipitation

Teicoplanin 4 mg/mL +
sodium citrate 22 g/L

0.4–0.6 mg/mL

Bioactivity reported by authors up to 14 days
stored at 4°C

Visual stability at 7 days at 25°C and 37°C
in glass tubes confirmed for the following
combinations: teicoplanin 0.02–0.5 mg/mL +
amikacin 0.02–0.05 mg/mL; teicoplanin
0.02–2 mg/mL + amikacin 0.02–3 mg/mL +
heparin 700–10,000 units/mL; teicoplanin
4–10 mg/mL + amikacin 0.02–3 mg/mL +
heparin 3,000–10,000 units/mL

Precipitation noted; levofloxacin 5 mg/mL used
without additive

,10% variability at 10 days at 37°C in glass tubes

Visual confirmation of physical compatibility

Sodium citrate 22 g/L

0.2–0.8 mg/mL

Visual stability at 7 days at 25°C and 37°C in glass
tubes confirmed for the following combinations:
teicoplanin 0.1 mg/mL + ciprofloxacin 0.1 mg/mL +
heparin 7–10,000 units/mL; teicoplanin
0.2 mg/mL + ciprofloxacin 0.2 mg/mL + heparin
700–10,000 units/mL; teicoplanin 0.4–2.0 mg/mL +
ciprofloxacin 0.4 mg/mL + heparin 3,500–
10,000 units/mL; teicoplanin 4 mg/mL +
ciprofloxacin 0.8 mg/mL + heparin 10,000 units/mL
Authors report visual stability at 7 days at 25°C
and 37°C in glass tubes
Visual stability confirmed at 7 days at 25°C and
37°C in glass tubes for ciprofloxacin 0.4 mg/mL
in combination
,10% variability at 72 hours at 37°C in glass tubes

Stability comments

Teicoplanin 0.1–4 mg/mL +
heparin 7–10,000 units/mL

Additives and
concentrations

0.1–1 mg/mL

Antibiotic
concentrations

Dwell time of 24 hours, changed
daily; duration of 5 days
Dwell time 12 hours/day;
changed daily; duration of 14 days

Dwell time minimum of
12 hours/day, changed daily;
Duration of 7–14 days

Dwell time up to 72 hours
between HD sessions

Dwell time/duration (if
applicable)

In vivo study

In vivo study

In vitro stability
study

In vitro bioassay
stability study
In vitro stability
study
In vitro stability
and bioactivity
study
Case series

In vitro bioassay
stability study
In vivo study

In vitro stability
study
In vitro stability
study

In vitro stability
study

Type of
investigation(s)

Justo and Bookstaver
Dovepress
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Gentamicina,34,38,45,48,63,95,110,111

No additives
Vancomycin 5 mg/mL +
heparin 5,000 units/mL
Heparin
5,000 units/mL
No additives

5 mg/mL
5 mg/mL

Teicoplanin
0.02–2 mg/mL + heparin
7–10,000 units/mL
Heparin 2,500 units/mL +
vancomycin 2.5 mg/mL +
cefazolin 5 mg/mL
Teicoplanin 4 mg/mL +
citrate 22 g/dL
Heparin 10 units/mL

0.02–2 mg/mL

1 mg/mL

Daptomycin 1 mg/mL +
citrate 28 mg/mL + LR
EDTA 30 mg/mL

Heparin 10 units/mL

3 mg/mL

5 mg/mL

5 mg/mL

Citrate 40 mg/mL

2.5 mg/mL

2.5 mg/mL

2, 4 mg/mL

Citrate 40 mg/mL

0.32 mg/mL

0.1 mg/mL

40 mg/mL

20 mg/mL
Heparin
100 units/mL
Heparin
5,000 units/mL

Heparin 20 units/mL

2 mg/mL

10 mg/mL

No additives

2 mg/mL

Visual confirmation of physical compatibility

Visual confirmation of physical compatibility
for 72 hours in glass tubes at 25°C and 37°C

At 37°C, no decrease in gentamicin or
citrate concentration at 96 hours; at room
temperature, 100% of gentamicin and 101.3%
citrate retained for 112 days
Refer to Daptomycin section in this table

Gentamicin 2 mg/mL + teicoplanin 4 mg/mL +
citrate compatible at 37°C for 7 days
Visual confirmation of physical compatibility

At 25°C and 37°C, gentamicin 0.02 and teicoplanin 0.02
compatible at all heparin concentrations; gentamicin
0.2–1 mg/mL, teicoplanin 0.2–1 mg/mL + heparin
3,500–10,000 units/mL compatible for 7 days
Compatibility confirmed at 37°C for 72 hours

At 4°C, compatible and stable for up to
4 weeks; confirmed via particle-enhanced
turbidimetric inhibition immunoassay
Visual confirmation of physical compatibility

Visual confirmation of physical compatibility

Visual confirmation of physical compatibility

Visual confirmation of physical compatibility

Visual confirmation of physical compatibility

Dwell time 12–24 hours

Dwell time 12–24 hours;
duration up to 15 days

Dwell time up to 72 hours
between HD sessions

Dwell time up to 72 hours
between HD sessions

Dwell time of 12 hours/day;
changed every 12 hours;
duration 10–14 days
Dwell time minimum of
72 hours; duration of 3–14 days
Dwell time 12–24 hours;
duration 11 days
Dwell time of 72 hours;
duration of 3 days
Dwell time up to 72 hours
between HD sessions
Dwell time 12–24 hours;
duration 3 days
Continuous dwell changed every
8 hours; duration of 14 days

submit your manuscript | www.dovepress.com

Dovepress

(Continued)

In vitro stability
study
In vitro
bioactivity study;
animal model
In vitro
bioactivity study

In vitro stability
studies

In vitro stability
study
Case series

In vivo study

In vitro stability
and bioactivity
study

In vivo study

In vitro stability
study

In vivo study

In vivo study

Case report

In vivo study

Case report

In vivo study

Case report
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Glycopeptides
Vancomycina,20,22,23,39,40,46,70,95,104,106,107,110,113–121

Tobramycin20,34,36,112

Antibiotic class/agent

Table 2 (Continued)

Heparin 5,000 units/mL
Colistin 0.1 mg/mL + heparin
100 units/mL
Heparin 100 units/mL

0.1 mg/mL
0.1 mg/mL

No additives
Citrate 40 mg/mL

Heparin 20 units/mL
Heparin 100 units/mL

1 mg/mL
1 mg/mL

2 mg/mL
2 mg/mL

0.5 mg/mL

Heparin 5,000 units/mL

5 mg/mL

0.025 mg/mL

TPA 1 mg/mL

5 mg/mL

Heparin 100 units/mL

TPA 0.875 mg/mL

2.4 mg/mL

0.025 mg/mL

Vancomycin 10 mg/mL +
heparin 10–5,000 units/mL
Sodium citrate 40 mg/mL

5 mg/mL

Heparin 9.75 units/mL

Heparin 5,000 units/mL

5 mg/mL

0.025 mg/mL

Heparin 1,000 units/mL

Additives and
concentrations

5 mg/mL

Antibiotic
concentrations

Bioassay stability sampling confirmed ,10%
loss of activity at 10 days at 25°C and 37°C in
polystyrene test tubes; addition of susceptible
bacteria and no impact on stability
Bioactivity reported by authors up to 14 days
stored at 4°C
At 4°C, RT, or 37°C, .92% of vancomycin
concentration at 72 hours with storage in
polyvinyl chloride syringes of HD catheters
Visual confirmation of compatibility; prepared
every 3 days and stored at 4°C
Vancomycin concentration of $0.130 mg/mL
retained for up to 28 days

Refer to Colistin section in this table

At 4°C, vancomycin concentration stable for
14 days; at 37°C, concentration reduced by
15%–37% at 24 hours
At 4°C and 27°C, compatible and stable
for 72 hours; at 40°C, 81% of vancomycin
concentration retained at 72 hours
At 4°C, compatible and stable for up to 4 weeks

At 4°C or room temperature, vancomycin
concentrations stable for 40 days

92% of gentamicin concentration retained
at 72 hours
Mild haziness on preparation, dissipated with
time and warming
Stability and compatibility confirmed at
48 hours at 23°C and 37°C
Stability and compatibility confirmed at
12 hours room temperature
Visual confirmation of physical compatibility
up to 48 hours

Visual confirmation of physical compatibility

Stability comments

Dwell times of 8–12 hours per
day; duration of 14 days
Dwell time 4–28 days in ports
of patients

Dwell time 12 hours/day;
changed daily; duration of 14 days

Dwell times variable in adult
cancer patients

Dwell times variable in neonates

Dwell times of 72 hours with
HD sessions

Dwell time 12–24 hours;
duration up to 15 days
Dwell time 12–24 hours;
duration up to 15 days
Dwell time 12–24 hours;
duration up to 15 days

Dwell time/duration (if
applicable)

In vivo studies

In vivo study

In vitro stability
study

In vivo study

In vitro bioassay
stability study; in
vivo study
In vitro stability
study; in vivo
study
In vitro stability
study; in vivo
study
In vitro stability
study
In vitro stability
study
In vitro bioassay
stability study

In vitro stability
study
In vivo study;
case series
In vivo study

Case series; in
vivo study
In vitro stability
study
Case series

Type of
investigation(s)

Justo and Bookstaver
Dovepress
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Teicoplanin38,122,123

Infection and Drug Resistance 2014:7
No additives
Citrate 40 mg/mL

TPA 1 mg/mL
No additives
Heparin 2,500 units/mL
Citrate 22 mg/mL

Citrate 40 mg/mL
Heparin 5,000 units/mL

Gentamicin 8 mg/mL +
heparin 5,000 units/mL

3 mg/mL
3 mg/mL

5 mg/mL
5 mg/mL
5 mg/mL
5 mg/mL

5 mg/mL
10 mg/mL

10 mg/mL
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4 mg/mL

0.02–10 mg/mL

0.02–2.0 mg/mL

Ciprofloxacin 0.1–1 mg/mL +
heparin 7–10,000 units/mL
Gentamicin 0.02–2 mg/mL +
heparin 7–10,000 units/mL
Amikacin 0.02–4 mg/mL +
heparin 7–10,000 units/mL
Ciprofloxacin 0.4–0.6 mg/mL
+ sodium citrate 22 mg/mL

Heparin 2.5 units/mL

2.5 mg/mL

0.1–4.0 mg/mL

Citrate 40 mg/mL

2 mg/mL

Heparin 10–10,000 units/mL

Citrate 22 mg/mL

2 mg/mL

0.02–10 mg/mL

Heparin 2,500 units/mL

2 mg/mL

Refer to Ciprofloxacin section in this table

Refer to Amikacin section in this table

Refer to Gentamicin section in this table

Visual compatibility confirmed at 7 days at
25°C and 37°C in glass tubes
See ciprofloxacin section

At 37°C, .90% of vancomycin concentration
at 72 hours and physically compatible
Initial precipitation, but no precipitation noted
after 10 minutes of incubation at 37°C; .90%
of vancomycin concentration over 72 hours
Physically compatible; at 37°C, .90% of
vancomycin concentration retained over 72 hours
In glass test tubes stored at 37°C, no change in
vancomycin concentration over 72 hours; in CVCs,
concentration decreased by 29.7% over 72 hours
Visual confirmation of physical compatibility

At 4°C, RT, or 37°C, .92% of vancomycin
concentration at 72 hours with storage in
polyvinyl chloride syringes of HD catheters
Visual confirmation of physical compatibility
up to 48 hours

At 37°C, stable for at least 72 hours and
physically compatible; at 37°C, .90% of
vancomycin concentration over 72 hours
Initial precipitation, but no precipitation noted
after 10 minutes of incubation at 37°C; .90%
of vancomycin concentration over 72 hours
Physically compatible; at 37°C, .90% of
vancomycin concentration retained over 72 hours
Decrease in vancomycin concentration gradient
from proximal to distal segments of dialysis
catheter at 48 hours

Dwell times up to 72 hours
between HD sessions; duration
of 2 weeks

Dwell times of 48 hours;
duration of 7 days

Dwell time 48 hours in HD
catheters

(Continued)

In vitro stability
study
In vitro stability
study
In vitro stability
study
In vitro stability
study
In vitro stability
study

In vitro stability
study
In vitro stability
study; in vivo
study
In vivo study

In vitro stability
study
In vitro stability
study

In vivo study

In vivo study

In vitro stability
study
In vivo study
with drug
concentration
analysis
In vivo study
In vitro stability
study

In vitro stability
study

In vitro stability
studies
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Lipopeptides
Daptomycin34,45,64,124–127

Oxazolidinones
Linezolid34,37,38,113

Telavancin39

Antibiotic class/agent

Table 2 (Continued)

Ethanol 25%
Heparin 100 units/mL
(reconstituted in LR)
Citrate 4% (supplemented
with calcium chloride
50 μg/mL)

2.5 mg/mL
5 mg/mL

5 mg/mL

1 mg/mL
Gentamicin 3 mg/mL +
citrate 28 mg/mL + LR

Heparin 2,000 units/mL

2 mg/mL

1 mg/mL

Heparin 100 units/mL

2 mg/mL

Heparin 5,000 units/mL
(reconstituted in 0.9% NS
and LR)
Heparin 100–1,000 units/mL

Citrate 20 mg/mL

1 mg/mL

1 mg/mL

Heparin 10–10,000 units/mL

Citrate 22 mg/mL, 0 mg/mL

2, 5 mg/mL

0.2–1.92 mg/mL

Heparin 2,500 units/mL

Gentamicin 2–4 mg/mL +
sodium citrate 22 mg/mL
Heparin 5,000 units/mL

Additives and
concentrations

2, 5 mg/mL

10 mg/mL

4 mg/mL

Antibiotic
concentrations

,5% decrease in daptomycin and heparin
concentrations at 14 days at 4°C and –20°C in
polypropylene syringes
Confirmation of physical stability based on
visual changes, absorbance, and pH for
48 hours at 23°C and 37°C in glass tubes

At 25°C, 90.7% and 86.7% of daptomycin
concentration retained at 48 and 72 hours,
respectively; 95.2% of gentamicin concentration
retained at 96 hours
Visual confirmation of physical compatibility

Visual compatibility confirmed for preparation

Visual compatibility confirmed at 72 hours at
25°C and 37°C in glass tubes

Visual confirmation of physical compatibility

Visual compatibility confirmed at 7 days at
25°C and 37°C in glass tubes
Confirmation of physical stability based on
visual changes, absorbance, and pH for
48 hours at 23°C and 37°C in glass tubes
Visual confirmation of physical compatibility

Physical and chemical stability at 72 hours at 37°C

Physical and chemical stability at 72 hours at
37°C; aPTT increased in 5 mg/mL solution

Visual confirmation of physical compatibility

Refer to Gentamicin section in this table

Stability comments

Dwell times 12–24 hours;
duration up to 15 days

Dwell time of 8 hours; duration
of 20 days
Dwell time up to 72 hours
between HD sessions

Dwell time up to 72 hours
between HD sessions; duration
of 21 days

Dwell time/duration (if
applicable)

In vitro stability
study

In vitro
bioactivity study
In vitro stability
study; in vivo
study

In vitro stability
study

In vivo study

In vitro
bioactivity study

In vivo study

Case report

In vitro stability
study
In vitro stability
study

In vitro stability
study

In vivo study

In vitro stability
study

Type of
investigation(s)

Justo and Bookstaver
Dovepress
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Vancomycin 0.1 mg/mL +
heparin 100 units/mL

Clarithromycin 200 mg/mL ±
heparin 1,000 units/mL

0.8 mg/mL

Compatibility and stability confirmed;
,10% degradation at 60 days at 4°C and
25°C; vancomycin had ∼25% decrease in
concentrations after day 15 at room temperature
Visual confirmation of physical compatibility
at 96 hours

Visual confirmation of physical compatibility

EDTA 30 mg/mL + ethanol
25% (referred to as “B-lock”)

0.1 mg/mL

Visual confirmation of physical compatibility
for up to 14 days (16 mg/mL solution)

Visual compatibility confirmed at 48 hours at
25°C and 37°C in glass tubes; color change
detected after 48 hours
Visual compatibility confirmed; samples stored
at -21°C until use

Bioactivity reported by authors up to 4 days
stored at 4°C
Visual compatibility confirmed

,10% decrease in daptomycin concentration
at 24 hours at 37°C

Heparin 100 units/mL

NAC 80 mg/mL + heparin
2,000 units/mL (heparin
100 units/mL in single case
report)

1 mg/mL

10, 16 mg/mL
(based on TMP
component)
5, 10 mg/mL

EDTA 30 mg/mL

EDTA 30 mg/mL ±
ethanol 25%

0.5 mg/mL

2–3 mg/mL

0.2 mg/mL

Heparin 5, 5,000,
10,000 units/mL
(reconstituted in LR)

Dwell times 12–72 hours;
duration 14 days

Dwell time 12 hours/day;
changed daily; duration of 14 days
Dwell times up to 7 days used

In vitro
bioactivity study

In vitro stability
study

In vitro
bioactivity study

In vivo study

In vivo study;
case report

In vitro
bioactivity study

In vitro
bioactivity study;
in vivo study

In vivo study

In vitro
bioactivity and
stability study; in
vivo study

Note: aSeveral published reports of gentamicin and vancomycin were not included in the table due to duplication of concentrations.
Abbreviations: aPTT, activated partial thromboplastin time; CRBSI, catheter-related bloodstream infection; CVC, central venous catheter; EDTA, ethylenediaminetetraacetic acid; HD, hemodialysis; LR, lactated ringer’s solution; NAC,
N-acetylcysteine; NS, normal saline; RT, room temperature; TPA, tissue plasminogen activator; TMP, trimethoprim.

Polymyxins
Colistin46,47

Trimethoprim128,132

Folate antagonists
Sulfamethoxazole/trimethroprim27,128

Glycylcyclines
Tigecycline45,130,131

Tetracyclines
Minocycline40–42,69,70,128,129

5 mg/mL,
25 mg/mL
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utilized solutions in CRBSI prophylaxis. Amikacin in combination with heparin alone and with vancomycin in solution
has demonstrated stability. Higher concentrations of amikacin (.10 mg/mL) have been associated with ototoxicity.18
These concentrations pose a significant risk to the patient,
especially when flushed into systemic circulation, and should
not be utilized in a lock solution. Gentamicin is among the
most studied antibiotics in lock solution. Despite the large
number of in vitro and in vivo studies, concern remains
about its relative compatibility and stability with heparin
in solution. Conflicting results in the literature suggest the
development of cloudiness or precipitation on preparation of
gentamicin plus heparin lock solutions.31 Although this may
be a concentration-dependent phenomenon, other factors
including the relative volumes of solution components, order
of preparation, temperature, and product manufacturers may
contribute. Although not extensively evaluated, exposure to
higher temperatures (eg, a catheter lumen) and elapsing time
have been suggested to improve the solution appearance.31
Data are mostly consistent in reporting compatibility of gentamicin concentrations ,4 mg/mL combined with heparin
concentrations .1,000 units/mL.32 Alternatively, extended
stability .100 days has been demonstrated for gentamicin
plus citrate in solution. Citrate-based solutions have shown
improved clinical outcomes when compared to heparinbased controls.33 The combination of gentamicin plus citrate
should be considered a viable option in both a prophylactic
and treatment modality. Tobramycin has also been studied in
combination with heparin, citrate, or TPA.20,34–36
Vancomycin in combination with heparin has been evaluated in a number of in vitro and clinical studies. Compatibility
with heparin has been consistently demonstrated at vancomycin concentrations ,10 mg/mL. Others have reported a visual
haze with higher concentrations of vancomycin (.5 mg/mL)
in combination with high concentrations of heparin (eg, 5,000
units/mL); however, these appear to be alleviated with slight
agitation.31 Vancomycin has also been shown to be compatible
in combination with citrate or TPA in solution. The combination of vancomycin plus citrate offers a nonheparinized
solution that may be beneficial in many patient populations.
Vancomycin has also been combined in solution with other
antibiotics including gentamicin with success. As previously
described, vancomycin activity against established biofilms
is concentration-dependent and has shown to be inferior
to comparator agents, including linezolid.37 Although not
clearly demonstrated, widespread use of vancomycin in a
prophylactic modality may increase the likelihood of developing resistance, and use in this manner should be cautioned.
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Teicoplanin as an alternative to vancomycin has demonstrated
similar compatibility with heparin up to 10,000 units/mL.
Varying compatibility has been reported for teicoplanin in
combination with citrate and other antimicrobials, including gentamicin and ciprofloxacin.38 Telavancin has shown
compatibility with heparin and citrate, however there are no
published reports of clinical use.39
Fluoroquinolones, specifically ciprofloxacin and levofloxacin, have been studied in a lock solution. Ciprofloxacin
at low concentrations in combination with heparin at low
concentrations (#2,500 units) has demonstrated stability
and compatibility. Incompatibilities have been reported with
higher concentrations of each component in solution. One
study confirmed visual stability of ciprofloxacin and citrate
for up to 7 days. Levofloxacin precipitation with heparin
has been noted, and published use of levofloxacin in a lock
solution is limited. Ciprofloxacin may offer an option for
management of gram-negative CRBSI.
Tetracyclines, most commonly minocycline, have been
utilized in ALT for nearly 30 years.40 The antibiofilm activity
and proposed synergy with ion chelators offer a promising
option as a lock solution. Minocycline in combination with
the ion chelator, EDTA, has demonstrated visual compatibility in a number of in vitro models and clinical studies.
Minocycline plus EDTA has demonstrated effectiveness in
preventing CRBSI in pediatric cancer patients and hemodialysis-dependent adults with dwell times up to 7 days.41–44
Doxycycline plus EDTA may be a promising alternative to
minocycline. Tetracyclines are not compatible with heparin.
The lack of consistent availability of EDTA may limit the
use of minocycline-based regimens. Future study with other
ion chelators (eg, citrate) is recommended.
Several agents that may be used for resistant grampositive infections including daptomycin, linezolid, and
tigecycline have been studied. Daptomycin has proven
stability with heparin and citrate at varying concentrations.
Reconstitution of daptomycin with Lactated Ringer’s solution (LR) or supplementation of the lock solution with calcium is required for activity.45 Use with ion chelators, such
as citrate, in solution cannot be recommended at this time
without confirmation of bioactivity. Linezolid stability with
heparin or citrate has been confirmed, although published
clinical use is quite limited. Because of the limitations of
linezolid therapy in CRBSI, its use as a lock solution should
be reserved for very specific cases with limited treatment
options. Tigecycline has been studied in combination with
N-acetylcysteine (NAC) and heparin in a lock solution with
positive clinical outcomes. Concerns with tigecycline use for
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bloodstream infections should limit its use to specific patient
cases as a lock solution.
Many other agents have been studied in a limited manner as lock solutions, including colistimethate, clindamycin,
macrolides, sulfamethoxazole/trimethoprim (SMX/TMP),
and rifamycins. Data for colistimethate and SMX/TMP are
included in Table 2. Stability data for colistimethate and
SMX/TMP are limited, but these may be potential options
for treatment of CRBSI secondary to MDRO.46 Clindamycin
use in a lock solution is limited to a single published study.26
Macrolides have been utilized in lock solutions in combination
due to their potential impact on biofilms.47,48 Rifamycins have
been studied as in vitro models, primarily in combination with
agents such as minocycline and ethanol. Because their use as a
primary agent in a lock solution would not be encouraged, they
are not discussed in this review.31 Dalbavancin, oritavancin,
tedizolid, and ceftaroline are new to the US market and have
not been studied in lock solutions.
Non-antibiotic antiseptics, such as ethanol and taurolidine, have also been used in a lock solution. Further, ion
chelators (eg, citrate, EDTA) without antibiotics in solution
are used in some institutions as the standard lock solution
as an alternative to heparin- or saline-based solutions.49,50
Ethanol combinations with antibacterials have been highlighted in this review, and further details of ethanol as a
potential lock solution are available elsewhere.14,31 Antifungal
agents lack extensive stability and compatibility data, and
their use is limited to select clinical cases. Available data are
discussed elsewhere.31,51

Logistical challenges
and common questions
While ALT represents a valuable option for many patients,
relative unfamiliarity with this treatment modality may result
in a delay or lack of ALT utilization. In order to optimize
clinical outcomes with ALT, clinicians should consider the
most common logistical challenges and questions for their
practice setting in advance. The development of standardized
protocols and/or institution-specific pathways may significantly improve utilization and success with ALT.

Preparation
The first step in considering ALT often requires locating
preparation information for the desired antibiotic lock
formulation. The development of local evidence-based
recipes for pharmacy use along with corresponding order
forms for prescriber use should significantly curb confusion
surrounding ALT. Standardizing antibiotic concentrations,
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additives, and product expirations used in local practice
should also increase familiarity and minimize the risk of medication errors with ALT. The information summarized herein
can serve as a useful tool in developing such materials.
A particularly important additive to consider is the anticoagulant. Any acute changes regarding the addition of an
anticoagulant, the specific agent used, and/or the concentration desired at the point of prescribing may render the current
stability/compatibility information, and thus the preparation
procedure, invalid. Such changes may significantly delay
ALT initiation. Therefore, clinicians developing local ALT
protocols should consider published evidence, availability of
the anticoagulant, and local patient populations (eg, hemodialysis or oncology vs general medicine patients) before
selecting a standard antibiotic lock formulation. Oftentimes,
providing two or three standard lock formulations for each
antibiotic agent may best suit local practice needs, such as
one with antibiotic alone and one coformulated with highconcentration heparin (5,000 units/mL) for hemodialysis
patients.
While heparin is historically the most common anticoagulant used in catheter locks, there is a growing body of
data supporting the use of alternative anticoagulants such as
the ion chelators, citrate or EDTA. A recent meta-analysis of
13 randomized controlled trials suggested citrate locks, specifically those coformulated with antibiotics, were superior
to heparin locks in preventing CRBSI in patients with hemodialysis catheters (risk ratio [RR]: 0.39, P,0.001).33 Citrate
locks were also associated with significantly lower risk of
bleeding events compared to heparin locks in this patient
population (RR: 0.48, P=0.002), yet outcomes regarding
catheter patency were comparable.33 In a 2010 position
statement on the management of hemodialysis-CRBSI, the
European Renal Best Practice (ERBP) supported ALT to
prevent CRBSI and specifically recommended citrate 4% as
the preferred agent/concentration.52 The beneficial effects
of citrate are likely secondary to its calcium-chelating
properties, which confer both antimicrobial and anticoagulant effects.53 The decreased risk of bleeding events is
likely secondary to the rapid metabolism of citrate in the
bloodstream.33 This latter property is advantageous in the
event of the citrate-containing lock being inadvertently
flushed into the systemic circulation. There are slightly
fewer clinical data regarding the use of EDTA in catheter
locks (mainly as preventive ALT in combination with
minocycline),41–44 but the results are promising. A clinical
study of a minocycline–EDTA lock as adjunctive treatment
of CRBSI is currently ongoing.54
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The debate over how and when to use anticoagulants
in ALT is still evolving; yet, product availability of the
alternative agents remains a potential logistical challenge.
Availability of EDTA varies significantly by country. The current available formulation in the US is the salt, calcium EDTA
200 mg/mL (also known as calcium disodium versenate).55
Its only US Food and Drug Administration (FDA)-approved
indication is the treatment of lead poisoning, meaning use
in catheter locks is off-label. An alternative formulation of
EDTA, edetate disodium, was removed from the US market
in 2008 secondary to fatal errors in adults and children where
the two EDTA formulations were confused and the incorrect
agent was administered.56 Thus, current use of EDTA as an
anticoagulant in ALT may be most appropriate as part of a
formal research protocol.
Citrate formulations have also faced safety concerns
and suffered from periodic market withdrawals. In 2000, the
FDA recommended against use of high concentration citrate
(46.7%) as a catheter anticoagulant due to a case of a patient
who experienced cardiac arrest, likely secondary to hypocalcemia, following a full-strength injection into a newly placed
hemodialysis catheter.57 This formulation was voluntarily
recalled in the US at the time and is now solely indicated as an
anticoagulant for granulocytapheresis procedures.57 It requires
dilution prior to use and direct IV infusion is contraindicated.
Additional serious adverse effects associated with high concentrations of citrate lock solutions continue to be reported
worldwide.58–60 The FDA currently recommends a lower citrate
concentration of 4% for use in catheter locks.61 The ERBP also
recommend a citrate 4% solution given its preferable benefit/
risk ratio compared to higher concentrations.52 Citrate 4%
formulations are available in the US and worldwide, yet many
are indicated solely for use in apheresis procedures (like the
high-concentration citrate product). In the European Union,
formulations of citrate 4% are available with the specific
indication for use in CVC, such as a solution of citrate 4%
alone (Citra-Lock™; Dirinco AG, Bern, Switzerland) and
one of taurolidine–citrate 4% in combination (Taurolock™;
Tauro-Implant GmbH, Winsen, Germany).61,62 Lastly, another
potential limitation of calcium chelators is the inability to
combine them with daptomycin locks until bioactivity of the
daptomycin has been confirmed.31,45
Another issue regarding antibiotic lock preparation
involves the relative waste of stock antibiotic solutions
when only a small amount of an IV product is used to formulate the lock (eg, a daptomycin 500 mg vial used for a
5 mg lock). Standardization of expiration dates may allow
for batch preparation of IV antibiotics with antibiotic locks,
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thereby minimizing product waste. Compliance with USP
797 guidelines for stability and compatibility of antibiotic
locks remains somewhat challenging as the majority of
current data is based on visual confirmation of physical
stability as opposed to higher quality methodology such as
high-performance liquid chromatography. However, there
are some data suggesting certain antibiotic lock formulations have extended stability, eg, gentamicin 2.5 mg/mL
and trisodium citrate 40 mg/mL, which are stable at room
temperature for 112 days.63 Such a formulation could be prepared in bulk and/or with IV doses of gentamicin. High cost
antibiotics (eg, linezolid, daptomycin) are typically reserved
for specific patient scenarios when these agents are selected
as the optimal concomitant systemic therapy.

Initiation and duration of therapy
When a CRSBI is suspected, discussion on catheter removal
versus salvage is likely to occur as part of an interdisciplinary
management decision with the patient and team. If catheter
salvage is being considered, even remotely, ALT should
also be considered. For treatment of CRBSI, ALT initiation
within the first 48–72 hours is associated with enhanced
outcomes,20,64 preventing infection-related sequelae and
improving the likelihood of catheter salvage. Delays of ALT
are often common in practice as the decision to attempt CVC
salvage may not be immediately known and other logistical
issues discussed herein may prevent a standard protocol
from being applicable for every specific case scenario.
Nevertheless, active ALT protocols should help prevent
treatment delay in a majority of patients.
Duration of ALT is often consistent with that of concurrent systemic therapy. Current guideline recommendations of
targeting 10–14 days of ALT are based on limited comparative
clinical data.5 Others have proposed abbreviated courses of
therapy of 72 hours.65,66 Often the intended duration of therapy
may be interrupted or shortened due to transitions of care,
especially upon hospital discharge. Early discussions with
case management and other personnel are needed to ensure
continuation of ALT beyond an inpatient stay, if necessary.
Although more data are needed to identify the optimal duration
of ALT, abbreviated courses may offer a more convenient,
cost-effective option and reduce the risk of resistance.

Dwell time and catheter accessibility
The optimal dwell time for ALT is unclear; however, the
majority of clinical studies have proposed a minimum of 8
hours per day, with targets of $12 hours per day to achieve
optimal sterilization.67,68 Several in vitro models have shown
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exposure times of approximately 4 hours being effective in
reducing bacterial colony counts, but the impact of shortened
exposure times is unavailable for many antibiotic–pathogen
combinations.45,69 Ideally, the solution may be locked in situ
whenever the CVC is not in use. Catheter access often limits
the dwell time, especially when the CVC is being used for
IV antibiotics and other systemic therapies. The nurse or
person responsible for medication administration should be
actively engaged to ensure replacement of the lock solution
if interruption of the dwell is required.
As alluded to above, the CVC is often being used for
additional systemic therapies because it is often the only
point of central venous access. Active discussions among
the interdisciplinary team, including the patient’s nurse, are
required to ensure proper profiling and scheduling of the lock
solution. Prior to profiling of the ALT, certain factors should
be considered: 1) the number of lumens for the specific CVC
and 2) IV therapies scheduled for administration through
the CVC (especially any continuous IV infusions). In cases
of a multi-lumen CVC, the optimal scenario is to lock all
lumens with the antibiotic solution. If a continuous IV fluid
is being administered in a patient with multiple lumens, the
nurse may be instructed to rotate lumens every 12–24 hours,
alternating the lock solution to allow for exposure of each
lumen to the ALT. This may present a significant challenge,
and proper labeling of CVC lumens can be used to identify
a rotation schedule. However, if a significant number of
scheduled IV therapies are expected, an attempt should be
made to coadminister them wherever possible (based on
known compatibility data). Alternatively, holding continuous
infusions like fluids or TPN for brief (24–36 hour) periods
initially70 or changing the administration to a peripheral IV
access may be viable options in select patients.

Risks of antibiotic lock therapy
There are a number of potential and documented risks associated with ALT. As with any solution allowed to dwell in a
catheter lumen, the potential for occlusion exists. This risk
is expected to be decreased if the solution also contains an
anticoagulant. Flushing of the lock solution may expose the
patient to unnecessary systemic concentrations of antibiotics
and/or anticoagulants – a risk that increases with flushing
frequency. Although some systemic exposure from CVC
leakage may be expected, the risk of toxicity is likely quite
limited if the lock is aspirated as directed. However, highconcentration antibiotic solutions associated with serious
toxicities, eg, aminoglycosides and ototoxicity, should still
be avoided.18 The greatest risk of flushing is likely in lock
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solutions containing higher concentrations of anticoagulants,
particularly heparin .1,000 units/mL or citrate 30%–46.7%.
At these concentrations, the patient may be exposed to systemically active doses that would increase risk of bleeding
or hypocalcemia and arrhythmias, respectively.57,71 Low-level
exposure of antibiotics may potentially increase the risk of
resistance.72,73 However, this concern should be weighed
against findings that routine prophylactic use of ALT may
reduce the general rate of CRBSI, thereby decreasing overall
need for systemic antibiotic therapy.15,33

Conclusion
Given the integral role of long-term CVC use in health care
delivery, ALT remains an important option for the preventive
and adjunctive treatment of CRBSI. A wide variety of antibiotics have been evaluated for clinical use, with the largest body
of data available for vancomycin and gentamicin. In order to
ensure optimal clinical outcomes with ALT, clinicians should
consider common technical questions and logistical challenges
in advance. These include lock preparation procedures, use of
additives (eg, heparin, citrate, or EDTA), timing of initiation
and therapy duration, dwell time and catheter accessibility, and
risks associated with ALT. Development of local protocols is
recommended in order to assist clinicians with these potential
issues and facilitate utilization of ALT where appropriate.
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